EN
HI

MOREPEN LAB. Share price

MOREPENLAB

HealthcareMid

60.57

0.39 (-0.64%)
NSE
BSE
Last updated on 16 May, 2025 | 15:52 IST
BUYSELL
Today's High

61.40

Today's Low

60.42

52 Week Low

42.00

52 Week High

100.90

The current prices are delayed, login to your account for live prices

Morepen Laboratories Chart

MOREPEN LAB. Share Key Metrics

Volume
30.52 L
Market Cap
3318.96 CR
LTQ@LTP
21@60.57
ATP
60.84
Var Margin
26.4 %
Circuit Range
48.76-73.15
Delivery %
30.35 %
Value
18.57 CR
ASM/GSM
No
Market Lot
1

MOREPEN LAB. Futures & Options

Data Not Found

MOREPEN LAB. Corporate Actions

DateAgenda
2025-05-12Audited Results & Final Dividend
2025-02-10-
2025-02-06Quarterly Results
DateEvent TypeAgenda
2025-05-12Board MeetingAudited Results & Final Dividend
2025-02-10AGM/EGM-
2025-02-06Board MeetingQuarterly Results

MOREPEN LAB. News

Morepen Laboratories Q3 Results: Profit dips 10% to Rs 22 cr

Feb 08 2022 18:15:25
Read More

About MOREPEN LAB. AboutThe

NSE : 2259  
BSE : 500288  
ISIN : INE083A01026  

Morepen Laboratories Limited (MLL) was incorporated as a Private Limited Company on December 1 1984 and subsequently converted into a Public Limited Company on March 16 1992. MLL initially setup a bulk drug unit for the manufacture of 6 T.P.A. of Ampicillin Trihydrate (ATH) at a total project cost of Rs. 14.70 lacs. The manufacturing unit was set up at Village : Masulkhana Parwanoo District : Solan in the state of Himachal Pradesh. Thereafter the Company has successfully undertaken a number of expansions and backward/forward integration projects.In November 1992 the Company made the maiden public issue of 2900000 equity shares of Rs. 10/- each for cash at a premium of Rs. 15/- per share to part finance an expansion cum backward integration project. The expansion was completed in October 1993.The Company undertook another expansion cum modernisation scheme in April 1994 for setting up facilities for manufacture of Loratadine (anti-allergic) and Cisapride (gastrointestinal disorders) in technical collaboration with Techquim Establishment Switzerland; modernisation/ expansion of existing antibiotics plant engaged in the manufacture of Ampicillin Trihydrate (ATH) Amoxycillin Trihydrate (AMX) Cloxacillin Sodium (CLX) and drug intermediate 6 Amino Pencillanic Acid (6APA) and for manufacture of new molecules namely Ketorolac (analgesic) and Omeprozole (anti-ulcer). The Project was completed in October 1994 as per the schedule of implementation mentioned in the Letter of Offer dated 7th February 1994.The technical collaboration agreement with Techquim Etablissement Switzerland was for sale of process know-how and production expertise for manufacture of Cisapride and Loratadine. The process know-how for manufacture of Cisapride and Loratadine has been fully absorbed and adopted by the Company.In August 1995 the Company undertook another expansion project for increasing its existing manufacturing facilities of bulk drugs.Present BusinessThe Company mainly manufactures bulk drugs which include Ampicillin Trihydrate (ATH) Amoxycillin Trihydrate (AMX) Cloxacillin Sodium (CLX) and 6 Amino Pencillanic Acid (6APA]. ATH AMX and CLX are semi synthetic pencillins used as Antibiotics. 6APA is a penicillin based intermediate used in the manufacture of Antibiotics. The bulk drugs are sold in both domestic as well as international markets.As a part of its forward integration plans the Company has entered the formulation industry. Generic formulations have been launched presently covering a range of 17 products like Ampicillin Trihydrate Amoxycillin Trihydrate Cephalexin Cipro Chloram Cotri Doxycycline Erythromycin Griseofulvin Ibuprofen Ibuprofen + Paracetamol Metronidazole Norfloxacin Omeprazole Ranitidine Rifampicin and Paracetamol. The ethical formulations have also been launched with a balanced product portfolio of 11 formulations of established molecules like Gastropen (for Gastro-oesophageal reflux disorders and Gastric Statis) Lanzopen (anti-ulcer) Claridin (anti-histamine) Loxipen (anti-bacterial) Studidom (for nausea & vomitting associated with vertigo) DOM-DT (Dispersible Domperidone for nausea & vomitting) Mormox (anti-biotic). Resporal (for respiratory tract infections) Normide (anti-bacterial & anti-protozoal) Imopen (for diarrhoea) and Eradiclox (anti-biotic).The Company''s present installed capacity for various products is as follows : (in mtpa)Drug Intermediate6 Amino Pencillanic Acid (6APA) 288Bulk DrugsAmpicillin Trihydrate (ATH) 180Amoxycillin Trihydrate (AMX) 240Cloxacillin Sodium (CLX) 60Ketorolac Omeprozole Loratadine and Cisapride 12Subsidiary CompanyAt present the Company does not have any subsidiary.

MOREPEN LAB. Management

NamePosition
Mr. Sushil Suri Chairman & Managing Director
Mr. Sanjay Suri Whole Time Director
Mr. Sukhcharan Singh Independent Director
Mr. Praveen Kumar Dutt Independent Director
Mr. Bhupender Raj Wadhwa Independent Director
Read More

MOREPEN LAB. FAQs

MOREPEN LAB. शेयर का खरीद मूल्य 60.57 है। लाइव प्राइस और तत्काल ट्रेडिंग के लिए, आप अपने चॉइस ट्रेडिंग खाते में लॉगिन कर सकते हैं या चॉइस के साथ मुक्त डीमैट खाता खोल सकते हैं।

MOREPEN LAB. शेयर खरीदने के लिए अपने चॉइस ट्रेडिंग खाते में लॉगिन करें, या चॉइस डीमैट खाता खोल, फिर फंड जोड़ें, कंपनी का नाम खोजें, अपना ऑर्डर टाइप चुनें और ट्रेड प्लेस करें।

MOREPEN LAB. शेयर का प्राइस-टू-अर्निंग्स (पी/ई) रेशियो 32.66 है। आप सापेक्ष मूल्यांकन के लिए इसकी तुलना सेक्टर के औसत से कर सकते हैं।

MOREPEN LAB. शेयर का प्राइस-टू-बुक (पी/बी) रेशियो 2.81 है। यह शेयर के मूल्य की तुलना उसकी बुक वैल्यू से करने में उपयोगी है।

MOREPEN LAB. शेयर का प्राइस-टू-बुक (पी/बी) रेशियो 4.77 है। यह शेयर के मूल्य की तुलना उसकी बुक वैल्यू से करने में उपयोगी है।

MOREPEN LAB. का मार्केट कैप 3318.96 CR है। यह कंपनी के आकार की श्रेणी और ट्रेडिंग लिक्विडिटी को दर्शाता है।

MOREPEN LAB. शेयर का 52 सप्ताह का उच्चतम और न्यूनतम मूल्य 100.90 और 42.00 है। ये मूल्य मूल्य सीमाएं, ट्रेडिंग रेंज, अस्थिरता, संभावित सपोर्ट/रेजिस्टेंस और मूल्य गति को दर्शाते हैं।